Enhanced Cancer Immunotherapy Using microRNA-155

Tumor immunotherapy is a promising approach for the treatment of cancer. However, current T cell-based immunotherapies are limited by the poor engraftment and functionality of the transferred T cells. Moreover, lymphodepleting regimens used to enhance engraftment and function of transferred tumor-reactive T cells are plagued by life-threatening side effects.

The scientists at the NIH recently discovered that the overexpression of microRNA-155 (miR-155) in tumor-reactive murine CD8+ T cells can enhance T cell proliferation and anti-tumor efficacy without lymphodepletion and exogenous cytokine administration. Consequently, using the miR155 overexpressing human CD8+ T cells could provide a safer, more effective T cell-based immunotherapy. This invention describes miR155 CD8+ T cell compositions and methods of using the miR155 CD8+ T cells to treat cancer through adoptive immunotherapy.

Potential Commercial Applications: Competitive Advantages:
  • Use in enhanced adoptive immunotherapy to treat cancer
  • T cells with enhanced proliferation, survival, and function
  • Robust tumor response without the need of lymphodepletion and exogenous cytokine support

Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Yun Ji (NCI)  ➽ more inventions...

Nicholas Restifo (NCI)  ➽ more inventions...

Luca Gattinoni (NCI)  ➽ more inventions...

Intellectual Property:
US Application No. 61/716,653
PCT Application No. PCT/US2013/065452
US Application No. 14/436,947

Dudda JC, et al. PMID 23601686

Collaboration Opportunity:

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of microRNA-155 to enhance T cell-based immunotherapies. For collaboration opportunities, please contact Luca Gattinoni at gattinol@mail.nih.gov or 301-451-6914, or Nicholas Restifo at restifo@nih.gov or 301-496-4904. Click here to view the NCI collaborative opportunity announcement.

Licensing Contact:
Abritee Dhal,
Email: abritee.dhal@nih.gov
Phone: 240-276-5530

OTT Reference No: E-272-2012-0
Updated: Oct 13, 2015